Hsu M, Willimsky G, Hansmann L, Blankenstein T
Front Immunol. 2025; 16:1518691.
PMID: 39931057
PMC: 11807957.
DOI: 10.3389/fimmu.2025.1518691.
Chaudhary P, Chaudhary S, Patel F, Patel S, Patel D, Patel L
Indian J Hematol Blood Transfus. 2025; 41(1):10-22.
PMID: 39917513
PMC: 11794774.
DOI: 10.1007/s12288-024-01808-9.
Harris Jr T, Trader D
RSC Med Chem. 2025; .
PMID: 39867589
PMC: 11758578.
DOI: 10.1039/d4md00787e.
Decroos A, Meddour S, Demoy M, Piccirilli N, Rousselot P, Nicolini F
Front Immunol. 2024; 15:1473139.
PMID: 39620210
PMC: 11604645.
DOI: 10.3389/fimmu.2024.1473139.
Lebon C, Grossmann S, Mann G, Lindner F, Koide A, Koide S
Cell Commun Signal. 2024; 22(1):500.
PMID: 39415233
PMC: 11483992.
DOI: 10.1186/s12964-024-01874-6.
BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph leukemias?.
Cruz-Rodriguez N, Tang H, Bateman B, Tang W, Deininger M
Leukemia. 2024; 38(9):1885-1893.
PMID: 39098922
PMC: 11569815.
DOI: 10.1038/s41375-024-02365-w.
Pharmacotherapy and cardiovascular challenges: a case report of olverembatinib-induced myocardial infarction with non-obstructive coronary arteries.
Xue H, Wang L, Ma Y, Hou C
BMC Cardiovasc Disord. 2024; 24(1):332.
PMID: 38956489
PMC: 11221000.
DOI: 10.1186/s12872-024-04011-w.
Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia.
Vysochinskaya V, Dovbysh O, Gorshkov A, Brodskaia A, Dubina M, Vasin A
Biomolecules. 2024; 14(6).
PMID: 38927048
PMC: 11201692.
DOI: 10.3390/biom14060644.
Anchored-fusion enables targeted fusion search in bulk and single-cell RNA sequencing data.
Yuan X, Wang H, Sun Z, Zhou C, Chu S, Bu J
Cell Rep Methods. 2024; 4(3):100733.
PMID: 38503288
PMC: 10985232.
DOI: 10.1016/j.crmeth.2024.100733.
MXene-Based Chemo-Sensors and Other Sensing Devices.
Navitski I, Ramanaviciute A, Ramanavicius S, Pogorielov M, Ramanavicius A
Nanomaterials (Basel). 2024; 14(5).
PMID: 38470777
PMC: 10934514.
DOI: 10.3390/nano14050447.
CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26).
Kim J, Kang K, Park Y, Kim B
Heliyon. 2023; 9(11):e22091.
PMID: 38045173
PMC: 10692791.
DOI: 10.1016/j.heliyon.2023.e22091.
Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with from Chronic Myeloid Leukemia (CML) in Blast Crisis.
Boucher L, Sorel N, Desterke C, Chollet M, Rozalska L, Gallego Hernanz M
Int J Mol Sci. 2023; 24(20).
PMID: 37895120
PMC: 10607477.
DOI: 10.3390/ijms242015441.
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.
Cross N, Ernst T, Branford S, Cayuela J, Deininger M, Fabarius A
Leukemia. 2023; 37(11):2150-2167.
PMID: 37794101
PMC: 10624636.
DOI: 10.1038/s41375-023-02048-y.
The Success of Treatment Free Remission in Chronic Myeloid Leukaemia in Clinical Practice: A Single-Centre Retrospective Experience from South Africa.
Hoosen S, Mackraj I, Rapiti N
Adv Hematol. 2023; 2023:2004135.
PMID: 37547186
PMC: 10403330.
DOI: 10.1155/2023/2004135.
Linear Phosphorylation Site Motifs for BCR-ABL Kinase Revealed by Phospho-Proteomics in Yeast.
Smolnig M, Fasching S, Stelzl U
J Proteome Res. 2023; 22(6):1790-1799.
PMID: 37053475
PMC: 10243146.
DOI: 10.1021/acs.jproteome.2c00795.
FUBP3 regulates chronic myeloid leukaemia progression through PRC2 complex regulated PAK1-ERK signalling.
Sharma M, Anandram S, Ross C, Srivastava S
J Cell Mol Med. 2022; 27(1):15-29.
PMID: 36478132
PMC: 9806296.
DOI: 10.1111/jcmm.17584.
Advancements on the Multifaceted Roles of Sphingolipids in Hematological Malignancies.
Raza Y, Atallah J, Luberto C
Int J Mol Sci. 2022; 23(21).
PMID: 36361536
PMC: 9654982.
DOI: 10.3390/ijms232112745.
Factors That Affect the Formation of Chromosomal Translocations in Cells.
Canoy R, Shmakova A, Karpukhina A, Shepelev M, Germini D, Vassetzky Y
Cancers (Basel). 2022; 14(20).
PMID: 36291894
PMC: 9600575.
DOI: 10.3390/cancers14205110.
Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies.
Bunce C, Khanim F, Drayson M
Blood Cancer J. 2022; 12(10):142.
PMID: 36202796
PMC: 9537160.
DOI: 10.1038/s41408-022-00738-x.
Creation of Philadelphia chromosome by CRISPR/Cas9-mediated double cleavages on BCR and ABL1 genes as a model for initial event in leukemogenesis.
Tamai M, Fujisawa S, Nguyen T, Komatsu C, Kagami K, Kamimoto K
Cancer Gene Ther. 2022; 30(1):38-50.
PMID: 35999358
PMC: 9842507.
DOI: 10.1038/s41417-022-00522-w.